Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected. Here's what you should know.
Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected.
Here's what you should know.
Viking Therapeutics stock is showing weakness.
What's pulling VKTX shares down?
Viking Beats Earnings Estimates but Stock Faces Selling Pressure The quarter ended June 30 produced a net loss of $1.10 per share, a figure that came in 12% better than the $1.25 loss analysts had been expecting.
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics launches Phase 1 trial for obesity drug VK3019, a dual amylin/calcitonin receptor agonist. Read about the…
The results could reinforce Eli Lilly and Novo Nordisk's dominance in the booming market for weight loss and diabetes drugs.
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other…
Here's a look at why Viasat stock is down after releasing its Q1 earnings report.
